MENU
natural progesterone scientific publications

Science Publications NATURAL PROGESTERONE:

  1. Adams, M. R., et al. Medroxyprogesterone Acetates Antagonize Inhibitory Effeets of Conjugated Eąuine Estrogens on Common Artery Atherossclerosis. .4r£mosc:/e/- Thromb YascBlol 17(1) (Janua­ry 1997): 217-21
  2. Aitken, M., D. M. Hart, and R. Lindsay. 1973. Oestrogen replacement therapy for prevention of osteoporosis after oopherectomy. British Medical Journal 3: 515-18
  3. Albright, F. Studies in ovarian function III: the menopause. Endocrinology 20, 1936; 24. Albright, F., P. H. Smith, and A. M. Richardson. 1941. Postmenopausal osteoporosis: its clinical features. JAMA 116: 2465-74
  4. Arafat, E. S., and J. T. Hargrove. Sedative and Hypnotic Effeets of Orał Administration of Micronized Progeśterone May Be Mediated through Its Meinbolites. American Journal of Obstetrics and Gynecology 159 (1988): 12034209
  5. Asch, R. H., and R. Greenblatt. Steroidogenesis in the Postmenopausal Ovary. Clinical Obstetr­ics and Gymcology 4(1) (1977): 85
  6. Ashcroft, G. S. et al. Estrogen Accelerates Cutaneous Wound Healing Associated with an Increa-se in TGF-beta 1 Levels. Naturę Medicine 3 (1997): 11.
  7. Aufrere, M. B. et al. Progeśterone: an Overview and recent Advances. J Pharmaceut Sci 65 (1976): 783.
  8. Backstrom, T. „Epileptic Selzure in Women Related to Plasma Oestrogen and Progeśterone during the Menstrual Cycle. Acta Neurol Scand 54 (1976): 321-347.
  9. Backstrom, T., et al. Estrogen and Progeśterone in Plasma in Relation to Premenstrual Tension. J Steroid Blochem Mol Biot 5 (1974): 257-260
  10. Backstrom, T., et al. Effeets of Ovarian Steroid Hormones on Brain Excitability and Their Relat­ion to Epilepsy Seizure Variation during the Menstrual Cycle. Advances in Eplleptology. Fifteenth Epilepsy International Symposium. New York: Raven Press.
  11. Balchetz, P E. 1994. Hormonal treatment of postmenopausal women. New England Journal of Medicine 330: 1062-71.
  12. Barnes, Broda. Hypothyroidism: The Unsuspected Illness. New York: Harper & Row, 1976. Barzel, U. S. 1988. Estrogens in the prevention and treatment of postmenopausal osteoporosis: a review. American Journal of Medicine 85: 847-50
  13. Bayer, S. R. et al. Clinical Manifestations and Treatment of Dysfunctional Uterine Bleeding Jo­urnal of the American Medical Association 269 (1993): 1823-1928.
  14. Bergkvist, L., H.-O. Adami, I. Persson, R. Hoover, and C. Schairer. 1989. The risk of breast cancer after estrogen and estrogen-progestin replacement. New England Journal of Medicine 321: 293-97.
  15. Beumont P. J. L. et al. Luteinizing Hormone and Progeśterone Levels after Hysterectomy. Bri­tish Medical Journal 836 (1972): 363
  16. Beynon, H. I. C., N. D. Garbett, and P. J. Barnes. Severe Premenstrual Exacerbations of Asthma: Effect of Intramuscular Progeśterone. Lancet (1988): 370-371.
  17. Bloom, T, A. Ojanotko-Harri, M. Laine, and I. Huhtaniemi. Metabolism of Progeśterone and Te-stosterone in Humań Parotid and Submandibular Salivary Glands in Vitro. J Steroid Blocfiem Mol Biot 44(1) (January 1993): 69-76
  18. Bourgain, C, et al. Effeets of Natura] Progeśterone on the Morphology of the Endometrium in Patients with Primary Ovarian Failure. Human Reproductioni 5 (1990): 537-543.
  19. Bower, B. Stress Hormones May Speed Up Brain Aging. Science News 153(17) (1998): 263. Bowman, K., et al. The Influence of Progeśterone and Androgens on the Growth of Endometrial Carcinoma. Cancer 71(11) (June 1, 1993): 3565-3569.
  20. Campbell, B. C, and P. T. Ellison. 1992. Menstrual variation in salivary testosterone among re-gularly cycling women. Horm Res 37: 132-36.
  21. Campbell, W. W., et al. Inureased Energy Reąuirements and Changes in Body Composition with Resistanee Training in Older Adults. American Journal of Clinical NutHtion 60(2) (1994): 167-175.
  22. Canterwall, B. S. Premenopausal Hysterectomy and Cardiovascular Disease. American Journ­al of Obstetrics and Gynecology 139 (1981): 58-61.
  23. Cavalieri, E. L., D. E. Stack, P. D. Devanesan, R. Todorovic, et al. Molecular Origin of Cancer: Ca-techol Estrogen-3, 4-quinones as Endogenous Tumor Initiators. Proc Natl Acad Sci 94 (1997): 10937-10942.
  24. Chang, K. J., et al. 1995. Influences of percutaneous administration of estradiol and progeśtero­ne on human breast epithelial celi cycle in vivo. Fertility and Sterllity 63: 785-91
  25. Christ, J. E., et al. The Residual Ovary Syndrome. Obstetrics & Gynecology 46 (1975): 551-556.
  26. Christiansen, C, M. S. Christiansen, and I. Transbol. 1981. Bonę mass in postmenopausal wo­men after withdrawal of estrogen/progestagen replacement therapy. Lancet February 28:459-61.
  27. Colbour
  28. Clark, G. M., and W L. McOuire. Progeśterone Receptors and human Breast CeWs. Breast Can­cer Research and Treatment 3 (1983): 157-163.
  29. Colbourn, Theo, et al. Our Stolen Futurę. New York: Penguin Books, 1977
  30. Colborn, T, F S. vom Saal, and A. M. Soto. 1993. Developmental effeets of endocrine-disrupting chemicals in wildlife and humans. Eiwironmental Health Perspectives 10: 378-84.
  31. Collins, P et al. Estrogen Replacement Therapy and Exercise Performance in Postmenopausal Women with Coronary Artery Disease. American Journal of Cardiology 81(2) (January 15, 1998): 259-260.
  32. Coney, Sandra. The Menopause Industry: How the Medical Establishment Exploits Women. Alameda, CA: Hunter House, 1994:
  33. Cooper, C, C. A. C. Wickham, D. J. R. Barker, and S. J. Jacobsen. 1991. Water fluoridation and hip fracture. JAMA 266: 513-14
  34. Corvol, R, et al. Effeets of Progeśterone and Progestins on Water and Salt Metabolism. Progeś­terone and Progestins. New York: Raven Press, 1983.
  35. Cowan, L. D., L. Gordis, J. A. Tonascia, and . S. Jones. 1981. Breast cancer incidence in women with a history of progeśterone deficiency. American Journal of Epidemiology 114:
  36. Cramer, S. R., D. C. Nieman, and J. W. Lee. The Effeets of Moderate Exercise Training on Psy-chological Well-Bein and Mood State in Women. Psychosomatic Research 35 (1991): 437-439.
  37. Crane, M. G., J. J. Harris, and W. Windsor III. 1971. Hypertension, orał contraceptive agents, and conjugated estrogens. Annals of Internat Medicine 74: 13-21.
  38. Cummings, S. R. M. C. Nevitt, W S. Browner, et al. 1995. Risk factors for hip fracture in white wo­men. New England Journal of Medicine 323: 767-73.
  39. Cundy, T., M. Evans, H. Roberts, et al. 1991. Bonę density in women receiving a depot medrox-yprogesterone acetate for contraception. British Medical Journal 303: 13-16.
  40. Dalsky, G. P, K. S. Stocke, A. A. Ehsani, et al. 1988. Weight-bearing exercise training and femoral neck and lumbar spine hone minerał density. Annals of Internal Medicine 108: 824-28.
  41. Dalton, K. The Aetiology of Premenstrual Syndrome Is with the Progeśterone Receptors. Medic­al Hypottieses 31 (1987): 321-327.
  42. Dalton, K. Erythema Multiforme Associated with Menstruation. Journal of the Itoyal Society of Medicine. 78 (1985): 787-788.
  43. Dalton, K. Once A Month. Hounter House, 1998
  44. Dalton, K. Progeśterone Suppositories and Pessaries in the Treatment of Menstrual Migraine. Headache 12 (1973): 151-159.
  45. Dalton, K. Tłie Premenstrual Syndrome and Progeśterone Therapy. Chicago: Year Book Me­dical Publishers, Inc., 1977; 2″a ed. London: Heinemann, 1984.
  46. Davis, D. L., H. L. Bradlow, M. Wolff, T.Woodruff, D. G. Hoel, and H. Anton-Culver. Medical Hypot-hesis: Xenohormones as Preventable Causes of Breast Cancer. Eiwironmental Health Perspectwes 101 (1993): 372-377.
  47. Dennerstein, L., C. Spencer-Gardner, J. B. Brown, M. A. Smith, and G. D. Burrows. Premenstrual Tension – Hormone Profiles. J Psychosomat Obstet Gynaec 3 (1984): 37-51.
  48. Dennerstein, L., et al. Progeśterone and the Premenstrual Syndrome: A Double-Blind Crossover Trial. British Medical Journal 290 (1985): 1017-1021.
  49. Devroey, R, G. Palermo, et al. Progesterone Administration in Patients with Absent Oyafles. In-ternational Journal of Fertility 34 (1990): 1S8-193.
  50. Ebeling, R, and V. A. Kotasto. 1994. Physiological importanee of dehydroepiandrosterone. Lan­cet 343: 147981.
  51. Eliasson, 0., and H. H. Scherzer. Recurrent Respiratory Failure in Premenstrual Asthma. Con­necticut Med 12 (1984): 777-778.
  52. Ellison, P. T. 1993. Measurements of salivary progesterone. Annals oftheNew YorkAcademy of Setehce September 20, 694: 161-76
  53. Ellison, P. T., S. E Lipson, M. T. 0’Rourke, G. R. Bentley, A. M. Harrigan, C. Painter-Brick, and V. J. Vitzhum. Population Variation in Ovarian Function (letter). Laiwet 342(8868) (August 14, 1993): 433-434.
  54. Ellison, P. T, C. Panter-Brick, S. E Lipson, and M. T. 0’Rourke. 1993. The ecological context of human ovarian function. Humań Rcproduction 8: 2248-58.
  55. Ettinger, B., H. K. Genant, and C. E. Cann. 1985. Long-term estrogen replacement therapy prevents bonę loss and fractures. Annals of Internat Medicine 102: 319-24.
  56. Felson; D. T., Y. Zhang, M. T. Hannan, D. P. Kieł, P. W. E Wilson, and J. J. Anderson. 1993. The effect of postmenopausal estrogen therapy on bose density in inderly women. New England Journal of Medicine 329: 1141-46.
  57. Formby, B., and T. S. Wiley. Progesterone Inhibits Growth and Induces Apoptosis in Breast Can­cer Cells: Inverse Effect on Expression of p53 and Bcl-2. Sansum Medical Research Foundation, Santa Barbara, Calif., 1997.
  58. Fried, Stephen. Bitter Hlls: Iuside the Hazardous World of Legał Drugs. New York: Bantam Books, 1998.
  59. Gaby, Alan R., M.D. Preuentinn and Reversing Osteoporosis. Rocklin, CA 95677: Prima Pu-blishing, P.O. Box 1260BK, 1993.
  60. Gallagher, J. O, W. T. Kable, and D. Goldgar. 1991. The effect of progestin therapy on cortical and trabecular bonę: comparison with estrogen. American Journal of Medicine 90: 171-78.
  61. Gambrell, R. D., Use of Progestogens in post-Menopausal Women. International Journal of Fertility 34 (1989): 315-321.
  62. Gambrell, R. D. 1982. The menopause: benefits and risks of estrogen-progestogen replacement therapy. Fertil Steril 37: 457-74.
  63. Garcia, C. R., and W. Cutler. Preservation of the Ovary: A Reevaluation. Fertility and sterility 42(4) (1985): 510-514,
  64. Gibbs, C. J., 1.1. Coutts, R. Lock, O. S. Finnegan, and R. J. White. Premenstrual Exacerbation of Asthma. Tiiorax 39 (1984): 833-836.
  65. Gillet, J. Y, Induction of Amenorrhea during Hormone Replacement Therapy: Optimal Microniz-ed progesterone Doses: A Multicenter Study. Maturitas 19 (1994): 103-116.
  66. Gompel, A., J. C. Sabourin, A. Martin, H. Yaneva, et al. Bcl-2 Expression in Normal Endometrium during the Menstrual Cycle. American Journal of Pathology 144 (1994): 1196-1202.
  67. Gordon, G. S., J. Picchi, and B. S. Root. 1973. Antifracture efficacy of long-term estrogens for osteoporosis. Traiis Assoc Am Physicians 86: 326-32.G
  68. Grant.EUen. The Bitter Pili: How Safe Is the Perfect Contraceptive? London: Elm, Tree Bo­oks, 1985
  69. Gruenigen, V. E., and J. R. Karlen. 1995. Carcinoma ofthe endometrium. American Family Physician, May 1: 1531-36.
  70. Hammond, C.B., F. R. Jelvsek, K. L. Lee, W. T. Creasman, and R. T. Parker. 1979. Effects of long-term estrogen replacement therapy. I. Metabolic effects. American Journal of Obstetrics and Gynecology 133: 525-36.
  71. Hanley, S. P. Asthma Variations with Menstruation. British J Dis Chest (1981): 306-308.
  72. Hargrove, J. T., W. S. Maxson, A. C. Wentz, And L. S. Burnett. 1989. Menopausal hormone replac­ement therapy with continuous daily orał micronized estradiol and progesterone. Obstetrics & Ginecology 71: 606-12
  73. Harris, Brian. 1994. Maternity blues and major endocrine changes: Cardiff puerporul mood and hormone study II, Wales. British Medical Journal, April 19, 308: 949-53.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2539811/
  74. Harris, B., L. Lovett, R. G. Newcombe, G. E Read, R. Walker, and D. Riad-Fahmy. Maternity Blues and major Endocrine Changes: Cardiff Puerperal Mood and hormone Study II (Wales). British Medic­al Journal April 9, 1994.
  75. Harris, S., et al. Influence of Body Weight on Rates of Change in Bonę Density of the Spine, Hip, and Radius in Post-Menopausal Women. Calcif Tisme Int 50 (1992): 19-23.
  76. Hata, K., et al. Effect of Regular Aerobic Exercise on Cerebrovascular Tonę in Young Women. Journal of Ultrasound Mcdwine 17(2) (February 1998): 133-136.
  77. Hedlund, L. R., and J. C. Gallagher. 1989. Increased incidence of hip fracture in osteoporotic wo­men treated with sodium fluoride. J Bonę & Miner Res 4: 223-25
  78. Henderson, B. E., R. K. Ross, M. C. Pikę, and J. T. Cassagrande. 1982. Endogenous hormones as a major factor in human cancer. Cancer Research 42: 3232-39
  79. Herman-Giddens, M. E., E. J. Slora, R. C. Wasserman, C. J. Bourdony, et al. Secondary sexual Characteristics and Menses in Young girls seen in Office Practice: A Study from the Pediatrie Resea­rch in Office Settings Network. Pediatrics 99 (1997): 505-512.
  80. Herzog, A. G. Intermittent Progesterone therapy and Freąuency of Complex partial Seizures in Women with Menstrual Disorders. Neurology 36 (1986): 1607-1610.
  81. Hiatt, R. A., R. Bawol, G. D. Friedman, and R. Hoover. 1984. Exogenous estrogen and breast can­cer after bilateral oophorectomy. Cancer 54: 139-44.
  82. Hoover, R., L. A. Gray, Sr., P. Cole, and B. MacMahon. 1976. Menopausal estrogens and breast cancer. New England Journal of Medicine  295: 401-405.
  83. Hreshchyshn, M. M., et al. Effects of Natural Menopause, Hysterectomy, and Oophorectomy on Lumbar Spine and Femoral Neck Bonę Densities. Obstetrics & Gynecology 72 (1988): 631-638!
  84. Hrushesky, W. J. M. Breast Cancer, Timing of Surgery, and the Menstrual Cycle: Cali for Pro-spective Trial. Journal of Women’s Health 5 (1996): 555-556.
  85. Hutchinson, T. A., S. M. Polansky, and A. R. Feinstein. 1979. Postmenopausal oestrogens protect against fractures of hip and distal radius: a case control study. Lancet W: 705-709.
  86. Jaszman, I. N. D. Van Light, and J. C. Saat. 1969. The perimenopausal symptoms: the statistical analysis of a survey. Parts A and B. Medical Gynecology Socwlogy 4: 268-76.
  87. Kamen, Betty. Hormone Replacement Tiierapy: Yes or No? Novato, CA 94948: Nutrition Encou-nter, Inc., P.O. Box 5847, 1993.
  88. Kandouz, M., M. Siromachkova, D. Jacob, B. C. Marąuet, et al. Antagonism between Estradiol and Progestin on Bcl-2 Expression in Breast Cancer Cells. International Journal of Cancer 68 (1996): 120-125.
  89. Kleerekoper, M. E., E. Peterson, E. Philips, D. Nelson, et al. 1989. Continuous sodium fluoride therapy does not reduce vertebral fracture ratę in postmenopausal osteoporosis (abstract). JBonę & Miner Res 4 (Suppl. 1): S 376
  90. Kradijan, Robert. Save Yourself from Breast cancer. New York: Berkley Books, 1994.
  91. Kushi, L. H. Physical ActMty and Mortality in Postmenopausal Women. Journal of the Amer­ican Medical Association 277(16) (April 1997): 1287-1292.
  92. LaPierre, A., et al. Exercise and Psychoneuroimmunology. Medicine and Science in Sports and Exercise 26(2) (1994): 182-190.
  93. La Vecchia, C, A. Decarli, E Parazzini, A. Gentile, C. Liberati, and S. Franceschi. 1986. Noncont-raceptive oestrogens and the risk of breast cancer in women. International Journal of Cancer 38″ 853-58.
  94. Landau, R. L., and K. Lugibihl. 1961. The catabolic and natriuretic effects of progesterone in man. Recent Progress in Hormone research. 17: 249-81.
  95. Leatber, A. T„ M. Savras, and J. W Stuidd. 1991. Endometrial histology and bleeding patterns after eight years of continuous combined estrogen and progestin therapy in postmenopausal women Obstet Gynecol 78: 1008-10.
  96. Lee, J. R. 1990. Osteoporosis reversal: the role of progesterone.Intern. ClinNutrReu 10: 384-91.
  97. Lee, J. R. 1990. Osteoporosis reversal with transdermal progesterone. Lancet 336: 1327.
  98.  Lee, J. R. 1991. Is natural progesterone the missingling in osteoporosis prevention and treatme-nt? Medical Hypotheses 35: 316-18.
  99. Lee, John R.,M.D. Natural Progesterojie: The Multiple Roles ofa Remarkable Hormone. Se-bastopol, CA 95473: BLL Publishing.
  100. Lee, John R., M.D., with Jesse Hanley, M.D., andVirginia Hopkins. Wiat Your Doctor May Not Tell about Premenopause: Balance Your Hormones And Your Life From Tliirty To Fifty. New York: Warner Books, 1999.
  101. Lee, John R., M.D., with Virginia Hopkins. Wlmt Your Doctor May Not Tell about Menojmuse: Tfie Breakthrough Book on Natural progesterone. New York: Warner Books, 1996.
  102. Lees, B., T. Molleson, T. R. Arnett, and J. C. Stevenson. 1993. Differences in proximal femur bonę density over twp centuries. Lancet 341: 673-75.
  103.  Leis, H. R, Endocrine Prophylaxis of Breast Cancer with Cyclic Estrogen and Progesterone. In­tern Surg 45 (1966): 496-503.
  104. Lennon, H. M., H. H. Woitiz, L. Parsons, and R J. Mozden. 1966. Reduced estriol excretion in pa-tients with.breast cancer prior to endocrine therapy. JAMA 196: 112-20.
  105. Lindsay, R., D. M. Hart, C. Forrest, and C. Baird. 1980. Prevention of spinał osteoporosis in oophorectomized women. Lancet II: 1151-54.
  106. Lipson, S. E, and P. T. Ellison, Reference Yalues for Luteal ‘Progesterone’ Measured by Salivary Radioimmunoassay. Fertility and Sterility 61(3) (March 1994): 448-454.
  107. Love, Susan. Dr. Susan Love’s Breast Book. Redding, Mass.: Addison-Wesley, 1990
  108. Lydon, J. R, E J. DeMayo, O. M. Conneely, and B. W. 0’Malley. Reproductive Phenotypes of the Progesterone Receptor Nuli Mutant Mouse. J Steroid Blochem Molec Biol 56 (1996): 67-77.
  109. Magill, P. J. Investigation of the Efficacy of Progesterone Pessaries in the Relief of Symptoms of Premenstrual Syndrome. British Journal of General Pfactice (November 1995): 598-593.
  110. Mahesh, V. B., D. W. Brann, and L. G. Hendry. Diverse Modes of Action of Progesterone and Its Metabolites. J Steroid Blochem Molec Biol 56 (1996): 209-219.
  111. Majewska, M. D. Steroid Hormone Metabolites Are Barbiturate-like Modulators of GABA system. Science 232 (1986): 1004-1007.
  112. Manolagas, S. C, R. L. Jilka, G. Hangoc, et al. 1992. Increased osteoclast development after es­trogen loss: mediation by interleukin-6. Science 257: 88-91.
  113. Matthews, K. A., et al. Prior to Use of Estrogen Replacement Therapy, Are Users Healtnier Than Nonusers? American Journal of Epidemiology 143(10) (1996): 971-978.
  114. Melillo, Mark. 1994. Estrogen use may predispose women to lupus. Medical Tribune, Novem-ber 17.
  115. Miyagawa, K., J. Rosch, E Stańczyk, and K. Hermsmeyer. Medroxyprogesterone Interferes with Ovarian Steroid Protection Against Coronary Vasospasm. Nature Medicine 3 (March 3, 1997): 324-327.
  116. Miles, R. A. Pharmokinetics and Endometrial Tissue Levels of Progesterone after Administ-ration by Intramuscular and Yaginal Routes: A Comparative Study. Fertility and Sterility 62 (1994): 485-490.
  117. Mohr, R E., D. Y. Wang, W. M. Gregory, M. A. Richards, and I. S. Fentiman: Serum Progesterone and Prognosis in Operable Breast Cancer. British Journal of Cancer 73 (1996): 1552-1555.
  118. Moyer, D. L., et al. Prevention of Endometrial Hyperplasia by Progesterone during Long-Term Estradiol Replacement: Influence of Bleeding Pattern and Secretory Changes. Fertility and sterility 59 (1993): 992-997.
  119. Munday, M. R., et al. Correlations between Progesterone, Oestradiol and Aldosterone Levels in the Premenstrual Syndrome. Clinical Endocrinology 14 (1981): 1-9.
  120. Munk-Jensen, N., S. P. Nielsen, E. B. Obel, and P. B. Eriksen. 1988. Reversal of postmenopausal vertebral bonę loss by oeslrogen and progestagen: a double-blind placebo-controlled study. British Medical Journal 296: 1150-52
  121. Nash, M. S. Exercise and Immunology. Medicine and Science in Sports and Exereise 26(2) (Fe-bruary 1994): 125-127:,,
  122.  Neugarten, B. L., and R. J. Kraines. 1964. Menopausal symptoms in women of various ages. Psy-choin Med 27: 266-73.
  123. Nillius, S. J., et al. Plasma Levels of Progesterone after Vagmal, Rectal or Intramuscular Admin-istration of Progesterone. American Journal of Obstetrics and Gynecology 110 (1971): 470-477.
  124. Northrup, Christiane, M.D. Women’s Bodies, Women’s Wisdom. New York: Bantam Bo­oks, 1994.
  125. Novak, E. R., et al., Enzyme Histochemistry of the Menopausal Ovary Associated with Nonnal and Abnormal Endometrium. American Journal of Obstetrics and Gynecology 93 (1965): 669.
  126. 0’Brien, P. M. S., C. Selby, and E. M. Symonds, Progesterone, Fluid and Electrolytes in Premens­trual Syndrome. British Medical Journal 1 (1980): 1161-1163.
  127. 0’Rourke, M. T., and P. T. Ellison. Age and Prognosis in Premenopausal Breast Cancer (letter; comment). Lancet 342 (8662) (July 3, 1993): 60.
  128. Ottoson, U. B., B. G. Johansson, and B. von Schoultz. 1985; Subfractions of high-density lipop-rotein cholesterol during estrogen replacement therapy: a comparison between progestogens and na­tural progesterone. American Journal of Obstetrics and Gynecology 151: 746-50.
  129. Peat, Raymond. From PMS to Menopause: Female Hormones in Context. Eugene, Ore.: Ray­mond Peat, 1997.
  130. Peat, Raymond. Nutrition for Women. Eugene, OR 97405: P.O. Box 5764, 1993.
  131. Peat, Raymond. Progesterone in Orthomolecidar Medicine. 1993.
  132. Pikę, M. C, D. V. Spicer, L. Dahmoush, and M. F. Press. 1993. Estrogens, progestogens, normal breast proliferation, and breast cancer risk. Epidem Rev 15: 64-82
  133. Prior, J. C. 1992. Letter. New England Jornal of Medicine 326: 705-706
  134. Prior, J. C. 1990. Progesterone as a bone-trophic hormone. Endocrine Reviews 11: 386-98
  135. Prior, J. C. 1991. Postmenopausal estrogen therapy and cardiovascular disease (letter). New En­gland Journal of Medicine 326: 705-706.
  136. Prior, J. C, B. Ho Huyen, R Clement, et al. 1992. Reversible luteal phase changes and infertility associated with marathon training. Lancet 1: 269-70.
  137. Prior, J. C, and Y. M. Vigna. 1990. Spinał bonę loss and ovulatory disturbances. New England Jornal of Medicine 223: 1221-27
  138. Prior, J. C, and Y. M. Vigna. 1991. Ovulation disturbances and exercise training. Glin Obstet Gynecol 26: 180-90.
  139. Prior, J. C, Y. M. Vigna, and N. Alojado. 1991. Progesterone and the prevention of osteoporosis, Canadian Journal of Obstetrics/Gynecology & Women’s Health Gore 3: 178-84
  140. Prior, J. C, Y. M. Vigna, N. Alojado, et al. 1987. Conditioning exercise decreases premenstrual symptoms: a prospective controlled six-month trial. Fertil Steril 47: 402-406.
  141. Prior, J. C, Y. M. Vigna, M. T. Schlechter, and A. E. Burgess. 1990. Spinał bonę loss and ovulatory disturbances. New England Journal of Medicine 323: 1221-27.
  142. Pujol, R, S. G. Hilsenbeck, G. C. Chamness, and R. M. Elledge. Rising Levels of Estrogen Recept­or hi Breast Cancer over 2 Decades. Cancer 74 (1994): 1601-1606.
  143. Raloff, J. Ecocancers. 1993. Science News, July 3. 144: 10-13 and reported in article Sperm-co-unt drop tied to pollution rise. Medical Tribune, March 26, 1992.
  144. Rannevik, G., et al. A Longitudinal Study of the Perimenopausal Transition: Altered Profiles of Steroid and Pituitary Hormones, SHBG and Bonę Minerał Density. Maturitas 21 (1995): 103-113.
  145. Ranney, B., et al. The Futurę Function and Fortune of Ovarian Tissue which is Retained in Vivo During Hysterectomy. American Journal of Obstetrics and Gynecology 128 (1977): 626-634.
  146. Raz, R., and W E. Stamm. 1993. A controlled trial of intravaginal estriol in postmenopausal wo­men with recurrent urinary tract infections. New England- Journal of Medicine 329: 753-56.
  147. Reid, I. R. Determinants of Total Body and Regional Bonę Minerał Density in Normal Postmen­opausal Women – A Key Role for Fat Mass. J Clin Endocrinol Metab 75 (1992): 45-51.
  148. Reidel, H. H., et al. Ovarian Failure Phenomena after Hysterectomy. Journal of Reproductive Medicine   31 (1986): 597-600.
  149. Reyes, F. L., J. S. Winter, and C. Faimari. 1977. Pituitary ovarian rełationships preceding the me­nopause: a cross-sectional study of serum follicle-stimulating hormone, luteinizing hormone, prolaet-in, estradiol and progesterone levels. American Journal of Obstetrics and Gynecology 129:557-64.
  150. Riggs, B. L., S. E Hondgson, W M. 0’Fallon, E. Y. S. Chao, et. al. 1990. Effect of fluoride treatment on the fracture ratę in postmenopausal women with osteoporosis. New England Journal ofMedic­
    ine     322: 802-809
  151. Riggs, B. L., H. W. Wahner, L. J. Melton, et al. 1986. rates of bonę loss in the appendicular and axial skeleton of women: evidence of substantial vertebral bonę loss before menopause. J Clinlnvest il7: UB7-m
  152. Rinzler, Carol Ann. Estrogen and Breast Cancer: A Wąrning to Women. New York: Macmillan Publishing, 1993.
  153. Róbbins, John. Reclaiming Out Health. Tiburon, Calif.: H. J. Kramer, 1996.
  154. Roof, R. L., et al. 1993. Gender influences outcome of brain injury: progesterone plays a protect-ive role. Bram res., April 2, 607(1-2): 333-36
  155. Rodriguez Macias, K. A. Catamenial Epilepsy: Gynecological and Hormonal Implications: Five Case Reports. Gynecology and Endocrinology 10 (1996): 139-142.
  156. Rodrkmez, C, E. E. Calle, R. J. Coates, H. L. Miracle-McMahill, M. J. Thun, and G. W. Heath. Es­trogen Replacement Therapy and Fatal Ovarian Cancer. American Journal of Epidemiology 141 (1995); 828-834.
  157. Rubinów, D. R., M. C. Hoban, G. N. Grover, D. S. Gailoway, P. Roy-Byrne, R. Andersen, and G. R. Merriam. Changes in Plasma Hormones across the Menstrual Cycle in Patients with Menstrually Re-lated Mood Disorders and in Control Subjects. American Journal of Obstetrics and Gynecology 158 (1988): 5-11.
  158. Rylance, R B., et al. Natural Progesterone and Antihypertensive Action. British Medical Journ­al 290 (1985): 13-14.   (
  159. Sabourin, J. C, A. Martin, J. Baruch, J. B. True, et al. Bcl-2 Expression in Normal Breast Tissue during the Menstrual Cycle. International Journal of Cancer 59 (1994): 1-6.
  160. Sahelian, Ray. DHEA: A Practical Guide, Avery Publishing, Garden City, N.Y.: 1996.
  161. Sahelian, Ray. Pregnenolone: A Practical Guide, Marina del Rey, Calif.: Melatonin/DHEA Re­search Institute, 1996.
  162. Sampson, G. A. Premenstrual Syndrome: A Double-Blind Contrplled Trial of Progesterone and Placebo. British Journal of Psychiatry 135 (1979): 209.
  163. Schmidt, Peter J., et al. Differential Behavioral Effects of Gonadal Steroids in Women with and in Those without Premenstrual Syndrome. New England Journal ofMedicine 338 (1998): 209-216.
  164. Seppa, N. Even Fraternal Twins May Share Cancer Risk. Science News 152 (December 1997): 389.
  165. Sherman, B. M., J. H. West, and S. G. Korenmam. 1976. The menopausal transition: analysis of LH, FSH, estradiol and progesterone concentrations during menstrual cycles of older women. J Glin Endocrinol Metab 42: 629-36.
  166. Shi:Zhong, B., Y. De-Ling, R. Xiu-Hai, J. Li-Zhen, et al. Progesterone Induces Apoptosis and Up-Regulation of p53 Expression in Humań Ovarian Carcinoma Celi Lines. American Cancer Society (1997): 1944-1950.
  167. Siddle, N., et al. The Effect of Hysterectomy on the Age at Ovarian Failure: Identification of a Su-bgroup of Women with Premature Loss of Ovarian Function and Literaturę Review. Fertiuty and Stehlity 47 (1987): 94-100.
  168. Simon, J. A. Micronized Progesterone: Vaginal and Orał Uses. Clinical Obstetrics and Gy­necology 38(4) (1995): 902-914.
  169. Sitruk-Ware, R., et al. Orał Micronized Progesterone. Contraceptión 36 (1987): 373. ’
  170. Snow-Harter, C. M. Bonę Health and Prevention of Osteoporosis in Active and Athietic Women. Clinics in Sports Medicine 13 (2) (April 1994): 389-404.
  171. Sovers, M. E R., M. K. Clark, M. L. Jannausch, and R. B. Wallace. 1991. A prospective study of bonę minerał content and fracture in communities with differential fluoride exposure. American Jo­urnal of Epidemiology 134: 649-60.
  172.  Stampfer, M. J., G. A. Colditz, W. C. Wiliett, et al. 1991. Postmenopausal estrogen therapy and cardiovaseular disease – ten-year follow-up from the Nurses’ Questionnaire Study. New England Jo­urnal of Medicine 325: 756-62.
  173. Steinberg, K. K., et al. Sex Steroids and Bonę Density in Premenopausal and Perimenopausal Women. J Glin Endocrinol Metab 69 (1989): 553-559.
  174. Stevenson, J. C, K. F Ganger, et al. 1990. Effects of transdermal versus orał hormone replaceme­nt therapy on bonę density in spine and proximal femur in postmenopausal women. Lancet 336: 265-69.
  175. Stone, S. C, et al. The Acute Effect of Hysterectomy on Ovarian Function. American Journal of Obstetrics and Gynecology 121 (1975): 193-197.
  176. Sulak, P J. The Perimenopause: A Critical Time in a Woman’s Life. International Journal of Fertiuty 41(2) (1996): 85-89.
  177. Swerdloff, R. S., and C. Wang. 1993. Androgen deficiency and agingin men. WJM159: 579-84.
  178. The Writing Group for the PEPI Trial, 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The postmenopausal estrogen/progestins in-teirentions (PEPI) trial. JAMA, January 18. 273(3): 240-41.
  179. Thompson, H. J. Effects of Physical Activity and Exercise on Experimen(ally Induced Mammary Carcinogenesis. Breast Cancer Research and Treatment 46 (2-3) (Kovember 1997): 135-141.
  180. Ursin, G. Orał Contraceptive Use and Adenocarcinoma of Cervix. Lancet 344 (8934) (1994): 1390-1394.
  181. Watson, N. R., and J. W W Studd. Bonę Loss Following Hysterectomy with Ovarian Conservati-on. European Journal of Obstetrics, Gynecology and. Reproductine Biology 49 (1993): 87.
  182. Weinberg, R. A. How Cancer Arises. Scientifie American (September 1996): 62-70.
  183. Wen, X. L., et al. Effects of Adrenocorticotropic Hormone, Humań Chorionic Gonadotropin, and Insulin on Steroid Production by Humań Adrenocortical Carcinoma Cells in Culture. Cancer Resea­rch 45(8) (August 1985): 3974-3978.
  184. Weiss, N. S., C. L. Ure, J. H. Ballard, A. R. Williams, and J. R, Daling. 1980. Decreased risk of fracture of hip and lower forearm with postmenopausal use of estrogen. New England Journal of Medicine 303: 1195-98
  185. West, Stanley, M.D. The Hysterectomy Hoax. New York: Doubleday, 1994.
  186. Wilson, P. W. E, R. J. Garrison, and W P. Castelli. 1985. Postmenopausal estrogen use, cigarette smoking, and cardiovascu!ar morbidity in women over 50. New England Journal of Medicine 313: 1038-43
  187. Willet, W. C, M. J. Stampfer, M. B. Colditz, et al. 1987. Dietary fat and the risk of breast cancer. New England Journal ofMedicine 316: 22-28
  188. Whitehead, M. I., D. Fraser, L. Schenkel, D. Crook, and J. C. Stevenson. 1990. Transdermal ad-ministration of estrogen/progestagen hormone replacement therapy. Lancet 335: 310-12.
  189. Witt, D. M., L. J. Young, and D. Crews. 1994. Progesterone and sexual behavior in males. Psychoneuroendocrinology 19: 553-56.
  190. Wojnarowska, F, et al. Progesterone-Induced Erythema Multiform. Journal of the Royal So­ciety of Medicine 78 (1987): 407-81.
  191. Wołk, A., et al. A Prospective Study of Association of Monounsaturated Fat and Other Types of Fat with Risk of Breast Cancer. Archwes of Internat Medicine 158 (1998): 41-45.
  192. Writing Group for the PEPI Trial. Effects of Estrogen or Estrogen/Progestin Regimens on Heart Disease risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventi-ons. Journal of the American Medical Association 273 (1995): 199-208.
  193. Zava, D. T, and G. Duwe. Estrogenie and Antiproliferative Properties of Genistein and Other Flavonoids in Humań Breast Cancer Cells in Vitro. Nutrition and Cancer 27 (1997): 31-40.

NATURALNY PROGESTERON

Copyright 2024 ©

Naturalny Progesteron/Natural Progesterone

ALL RIGHTS RESERVED